[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR087094A1 - Formulaciones que estabilizan proteinas - Google Patents

Formulaciones que estabilizan proteinas

Info

Publication number
AR087094A1
AR087094A1 ARP120102467A ARP120102467A AR087094A1 AR 087094 A1 AR087094 A1 AR 087094A1 AR P120102467 A ARP120102467 A AR P120102467A AR P120102467 A ARP120102467 A AR P120102467A AR 087094 A1 AR087094 A1 AR 087094A1
Authority
AR
Argentina
Prior art keywords
formulations
stabilize proteins
buffer
phosphate
therapeutic protein
Prior art date
Application number
ARP120102467A
Other languages
English (en)
Original Assignee
Gtc Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gtc Biotherapeutics Inc filed Critical Gtc Biotherapeutics Inc
Publication of AR087094A1 publication Critical patent/AR087094A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En un aspecto, la presente proporciona formulaciones que estabilizan proteínas, en donde las formulaciones comprenden un búfer. En algunas formas de realización, el búfer comprende mono-hidrógeno-fosfato de potasio y di-hidrógeno-fosfato de potasio, o el búfer comprende mono-hidrógeno-fosfato de sodio y di-hidrógeno-fosfato de sodio. En algunas formas de realización, la proteína es una proteína terapéutica. En algunas formas de realización, la proteína terapéutica es antitrombina.
ARP120102467A 2011-07-07 2012-07-06 Formulaciones que estabilizan proteinas AR087094A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161505354P 2011-07-07 2011-07-07

Publications (1)

Publication Number Publication Date
AR087094A1 true AR087094A1 (es) 2014-02-12

Family

ID=47437713

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102467A AR087094A1 (es) 2011-07-07 2012-07-06 Formulaciones que estabilizan proteinas

Country Status (10)

Country Link
US (1) US20140242182A1 (es)
EP (1) EP2729164A4 (es)
JP (1) JP6178311B2 (es)
KR (1) KR20140054026A (es)
CN (1) CN103945862A (es)
AR (1) AR087094A1 (es)
AU (1) AU2012278836B2 (es)
BR (1) BR112014000217A2 (es)
CA (1) CA2840876A1 (es)
WO (1) WO2013006766A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2823005C (en) 2010-12-30 2019-07-09 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Glycols as pathogen inactivating agents
MX2015001508A (es) 2012-08-03 2015-04-08 Lfb Usa Inc El uso de antitrombina en la oxigenacion por membrana extracorporea.
AU2014217561B2 (en) 2013-02-13 2018-11-15 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-TNF-alpha antibodies and uses thereof
BR112015019348A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
ES2793176T3 (es) 2013-07-05 2020-11-13 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa Matriz de cromografía de afinidad
IL272167B2 (en) * 2017-08-08 2024-02-01 Csl Behring Ag Mofexin formulations
CN117904091A (zh) * 2024-01-18 2024-04-19 武汉市长立生物技术有限责任公司 一种凝血酶稳定剂以及一种凝血酶时间测定试剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03215430A (ja) * 1990-01-19 1991-09-20 Kita Kiyoshi 関節腔抗凝固剤
JPH0236128A (ja) * 1988-07-25 1990-02-06 Kiyoshi Kita 眼内注射剤
US5135523A (en) * 1988-12-13 1992-08-04 Alza Corporation Delivery system for administering agent to ruminants and swine
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
DK0804070T3 (da) * 1993-03-09 2000-08-07 Genzyme Corp Fremgangsmåde til isolering af proteiner fra mælk
JP3822383B2 (ja) * 1993-12-17 2006-09-20 持田製薬株式会社 可溶性トロンボモジュリン含有組成物
US6268487B1 (en) * 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
JP2000290196A (ja) * 1999-03-31 2000-10-17 Welfide Corp 血圧低下抑制剤
US6448024B1 (en) * 2000-10-03 2002-09-10 Roche Diagnostics Corporation Method, reagent, cartridge, and device for determining fibrinogen
EP1549342A4 (en) * 2002-09-17 2006-05-10 Gtc Biotherapeutics Inc ISOLATION OF IMMUNOGLOBULIN MOLECULES TO WHICH HE LACKS DISULFIDE LINKS BETWEEN HEAVY CHAINS
FR2901796A1 (fr) * 2006-05-31 2007-12-07 Lab Francais Du Fractionnement Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US9884117B2 (en) * 2009-09-03 2018-02-06 Ablynx N.V. Stable formulations of polypeptides and uses thereof

Also Published As

Publication number Publication date
JP6178311B2 (ja) 2017-08-09
EP2729164A4 (en) 2015-05-06
US20140242182A1 (en) 2014-08-28
CA2840876A1 (en) 2013-01-10
KR20140054026A (ko) 2014-05-08
WO2013006766A3 (en) 2014-05-08
WO2013006766A2 (en) 2013-01-10
JP2014520820A (ja) 2014-08-25
EP2729164A2 (en) 2014-05-14
BR112014000217A2 (pt) 2017-02-07
CN103945862A (zh) 2014-07-23
AU2012278836A1 (en) 2013-05-02
AU2012278836B2 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
AR087094A1 (es) Formulaciones que estabilizan proteinas
CY1124024T1 (el) Νεες ctla4-ig ανοσοπροσκολλητινες
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CL2013003090A1 (es) Polipeptido que comprende una primera secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17f, il17-a/f, pero no a il-17a, y una segunda secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17a, il-17f y il17-a/f; composicion farmaceutica que lo comprende; y su uso.
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
ECSP13012384A (es) Composición acuosa que contiene bromhexina
AR087745A1 (es) Composiciones y metodos que comprenden una variante de enzima lipolitica
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CR20110091A (es) Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
CL2013003214A1 (es) Formulacion estable que comprende al menos un anticuerpo monoclonal que se une especificamente a pcsk9, un tampon, un surfactante y al menos un estabilizador; y su uso para tratar o prevenir enfermedades relacionadas con el colesterol.
UY34558A (es) Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
CR10528A (es) Proceso para producir poxvirus y composiciones de poxvirus
BR112013017080A8 (pt) Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
GT201200276A (es) Combinaciones de compuestos activos
CR11580A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
BR112013020767A2 (pt) composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo
AR082422A1 (es) Composicion detergente liquida
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.
CU23795A3 (es) Formulaciones líquidas de anticuerpo antirrábico
AR098168A1 (es) Formulación estable de insulina glulisina
EA201490948A1 (ru) Способ определения соблюдения гигиены рук
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
RS54875B1 (sr) Liofilizovane formulacije fgf-18

Legal Events

Date Code Title Description
FB Suspension of granting procedure